The GLP-1 receptor in airway inflammation in asthma: a promising novel target?
- PMID: 34425713
- PMCID: PMC8487967
- DOI: 10.1080/1744666X.2021.1971973
The GLP-1 receptor in airway inflammation in asthma: a promising novel target?
Keywords: Asthma; GLP-1; IL-33; ILC2.
Conflict of interest statement
Declaration of Interest:
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed
Figures
References
-
- Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services. 2020.
-
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157. - PubMed
-
- Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280–1290. - PubMed
-
- Viby N-E, Isidor MS, Buggeskov KB, et al. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013;154:4503–4511. - PubMed
-
- Hur J, Kang JY, Kim YK, et al. Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model. Pulm Pharmacol Ther. 2021;67:102003. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical